Crossmark

Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidemia influenced the management of dyslipidemia? The MEJORALO-CV Project

Crossref DOI link: https://doi.org/10.1016/j.rceng.2019.08.006

Published Print: 2020-06

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Giner Galvañ, V.

Bonig Trigueros, I.

Fácila Rubio, L.

Morillas Blasco, P.

Martínez Hervás, S.

Pascual Fuster, V.

Valls Roca, F.

Soler Portmann, C.

Tamarit García, J.J.

Pallarés Carratalá, V.

Cepeda Rodrigo, José María

Cosín Sales, Juan

Durá Belinchón, Rafael

Gómez Segado, Enrique

Monleón Arenós, Saray

Morillas Ariño, Carlos

Rodilla Sala, Enrique

Rovira Daudí, Eduardo

Vicente Navarro, David
Funding

Funding for this research was provided by:

Merck Sharp & Dohme Española S.A.
License Information

Text and Data Mining valid from 2020-06-01
More Information

This article is maintained by: Elsevier

Article Title: Have the Government's prescription algorithm and the 2013 American College of Cardiology/American Heart Association guidelines for managing dyslipidemia influenced the management of dyslipidemia? The MEJORALO-CV Project

Journal Title: Revista Clínica Española (English Edition)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.rceng.2019.08.006

CrossRef DOI link to the associated document: https://doi.org/10.1016/j.rce.2019.08.006

Content Type: article

Copyright: © 2019 Elsevier España, S.L.U. and Sociedad Española de Medicina Interna (SEMI). All rights reserved.

Document is current

Any future updates will be listed below